Outcomes of Focal Ablation for Prostate Cancer
Prospective Single Institutional Study Evaluating the Outcomes for Patients Undergoing Ablative Therapies in the Management of Clinically Localized Prostate Cancer in the Primary and Salvage Setting
About This Trial
- This study is testing a targeted treatment called focal ablation, which destroys only the cancerous areas of the prostate, to see how safely it controls cancer and affects everyday quality of life.
- It is open to adult men who have prostate cancer that is either newly diagnosed or has returned, as long as the cancer has not spread beyond the prostate.
- Before considering this trial, you should know that doctors will need to confirm the tumor is located in a spot that can be safely reached and treated.
- Additionally, you cannot participate if the cancer has spread to other areas or if you currently have an active urinary tract infection.
More Information
- This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.
Who Can Enroll
- Age Range: 18 - 90 years
- Gender: Male
- Who This Trial is For: This study is testing a targeted treatment called focal ablation, which destroys only the cancerous areas of the prostate, to see how safely it controls cancer and affects everyday quality of life.
Study Details
- Start Date: February 1, 2023
- Lead Sponsor: University of Texas Southwestern Medical Center
Full Eligibility Criteria
Inclusion Criteria
- Men with histologically confirmed prostate adenocarcinoma diagnosed on prostate biopsy
- Men with histologically confirmed local recurrence of prostate cancer diagnosed on prostate biopsy and Standard of Care imaging excluding locoregional or metastatic disease
- Age 18-90 years.
- Life expectancy > 1 year
- Ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria
- Anatomic abnormalities that do not allow for focal ablation
- Evidence of non-organ confined disease that is not feasible for ablation
- Has active urinary traction infection